Targeting the palm: a leap forward toward treatment of keratin disorders.

[1]  C. Contag,et al.  Generic and personalized RNAi-based therapeutics for a dominant-negative epidermal fragility disorder. , 2012, The Journal of investigative dermatology.

[2]  Chang-Hun Lee,et al.  Defining keratin protein function in skin epithelia: Epidermolysis Bullosa Simplex and its aftermath , 2011, The Journal of investigative dermatology.

[3]  S. Bracke,et al.  Lipid-mediated gene delivery to the skin. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  Jonathan E. Moore,et al.  Development of Allele-Specific Therapeutic siRNA in Meesmann Epithelial Corneal Dystrophy , 2011, PloS one.

[5]  Beverly L. Davidson,et al.  Current prospects for RNA interference-based therapies , 2011, Nature Reviews Genetics.

[6]  R. Hickerson,et al.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  E. Lane,et al.  The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases , 2008, Human mutation.

[8]  M. Omary,et al.  A mutation of keratin 18 within the coil 1A consensus motif causes widespread keratin aggregation but cell type-restricted lethality in mice. , 2007, Experimental cell research.

[9]  D. Roop,et al.  An Inducible Mouse Model for Epidermolysis Bullosa Simplex , 2001, The Journal of cell biology.

[10]  E. Fuchs,et al.  Functional Differences between Keratins of Stratified and Simple Epithelia , 1998, The Journal of cell biology.

[11]  K. Zatloukal,et al.  Lessons from Keratin 18 Knockout Mice: Formation of Novel Keratin Filaments, Secondary Loss of Keratin 7 and Accumulation of Liver-specific Keratin 8-Positive Aggregates , 1998, The Journal of cell biology.